Fritextsökning
Innehållstyper
-
Hypothesis testing versus conspiracy theory
"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
Orbán's extended arm becomes health commissioner in the EU
Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
Oavbrutet flöde med SMC:s nya clamp-on flödesmätare
SMC lanserar en clamp-on flödesmätare för vätska och stärker därmed positionen som innovativ aktör inom industriell automation världen över.
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...
-
Computed tomography in measurement of medical plastic products
Watch the recordings from ZEISS Quality Innovation Summit.
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
Mastering Urine Microscopy: Techniques for Accurate Disease Detection
Live Webinar on September 25, 2024.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...
-
100 years of Festo
The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
Getinge and Neobiomics received Swecare's export awards
Two companies received awards during Swecare's annual conference.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
Achieve Efficient, Fast Targeting of Your Sample
Step into the future of imaging technology with VersaXRM 730.
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"
For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
Novo Nordisk establishes new factory in Denmark
Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.
-
New features in ZEISS CALYPSO 2024
ZEISS CALYPSO is your universal software for dimensional metrology applications.
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...